AAV producer cell lines: Learning from mAbs
Get insights on how mAb production has evolved — and what it means for viral vectors.
Cell lines play a vital role in therapeutic production by providing a consistent and scalable source of biological materials essential for developing and manufacturing treatments. These cell lines can be engineered to produce high yields, ensuring the quality and efficacy of the final product. Cytiva offers solutions for protein, monoclonal antibody (mAb), and viral vector production through its GOCHO platform and ELEVECTA™ cell line portfolio, helping you accelerate your therapeutic journey.
Resources
Performant transient cell line with higher quality
Learn how we obtain efficient and scalable production of rAAVs across multiple serotypes with low levels of encapsidated hcDNA.
Developing GOCHO™ platform
A robust cell line development platform relies on a host cell line; learn more about our platform.
GOCHO™ robust workflow
We developed a workflow to increase the number of productive clones.
Robust AAV production with a true stable producer cell line
Read about upstream process development with the ELEVECTA™ producer cell line for AAV production.
Tailored cell lines for purity and sustainability
Explore a portfolio of engineered stable cell lines and their potential to transform the landscape of AAV production.
Increase titers while reducing mAb CLD time and effort
Learn how our site directed integration workflows give CLD flexibility to prioritize time/effort/cost as needed per project.
Improve bispescific antibody assembly and purity with GOCHO™
Generate clones expressing a 3-chain asymmetric BsAb with a total titer of > 6 g/L in a non-optimized 14-day fed-batch with GOCHO™ .